新京报讯(记者王卡拉)11月14日—16日，在由中国医促会临床营养健康学分会主办的"第八届华夏医学 营养论坛暨医学体重管理门诊的建设与规范化管理培训会议"上，减重相关多学科医学专家强调，肥胖 不是单纯的"体型问题"，而是涉及代谢、遗传、行为、饮食等多因素的复杂慢性疾病，其防治需要长期 科学管理，更离不开多学科团队的协同发力。随着更多医疗机构加入医学减重教学网络及各项指南规范 的深入落地，我国体重管理服务体系将不断完善。 医学营养治疗作为肥胖症治疗的基础，是贯穿肥胖自然病程、预防和控制肥胖及相关并发症的核心措 施，为科学减重提供了关键支撑。北京协和医院临床营养科陈伟教授指出，"十五五"规划建议中强调了 加强慢性病综合防控的重要性。《"健康中国2030"规划纲要》也提出，每个人是自己健康的第一责任 人，并强调了"三减"(减油、减盐、减糖)，实现健康口腔、健康体重、健康骨骼。"实际上这三个健康是 我们进行慢病防治的重要抓手。本次大会中特别倡导了'医学体重管理'这样一个名词，重点强调用医疗 的手段，即在医生的监督防控之下，让体重管理变得更安全、更有效，更加能够改善机体的代谢状况， 所以体重管理应该是慢病防治的桥头堡。 ...

Investment Dynamics - Marsala Biotechnology has completed a B+ round financing exceeding 100 million yuan, led by Baillie Investment and Baillie Zhigao, with existing shareholders also participating [3] - The funds will be used to enhance R&D and clinical trials, solidifying the company's leading position in the "clinical + consumer" dual scenarios [3] Company Developments - Berkshire Hathaway has reported a $3.8 billion impairment loss on its stake in Kraft Heinz, reducing the book value of its shares to $8.4 billion [5] - Kaluga Queen's parent company is considering an IPO in Hong Kong, with discussions ongoing regarding the scale of the offering [7] - Mr. Ice Cream is hiring for an IPO audit position, indicating potential plans for a Hong Kong IPO [9] - Goldman Sachs is set to acquire Froneri for €15 billion, utilizing a unique "continuation fund model" to manage the investment [13] - Bogner's parent company is selling 60% of its shares to Katjes International, enhancing Bogner's capital base for international expansion [16] - Cargill is selling its animal feed production business in Malaysia for approximately 231 million ringgit as part of a global restructuring [18] - Haoxiangni has launched a new series of craft beers, aiming to diversify its product offerings amid market challenges [20] - Kering and Swire Properties have established a sustainable development partnership to enhance ESG performance in retail [23] Personnel Changes - Walmart announced the immediate resignation of Ignacio Caride, CEO of Walmart Mexico and Central America, appointing Cristian Barrientos as interim CEO [25]

Core Viewpoint - Marsala (Shanghai) Biotechnology Co., Ltd. has completed a B+ round financing of 108 million yuan, aimed at enhancing R&D and clinical trials for its core products, solidifying its leading position in both clinical and consumer nutrition markets [1][3]. Group 1: Company Overview - Marsala is an innovative company focused on medical nutrition, with a comprehensive product matrix that includes special medical purpose formula foods, energy control weight loss nutrition foods, and DGI foods [1][2]. - The company has developed over 100 SKUs of medical nutrition products and holds 6 special medical permits and FDA registration, catering to diverse population needs from clinical treatment to chronic disease management and daily health interventions [1][2]. Group 2: Product Development and Innovation - Marsala has established specialized R&D centers in Shanghai and Taizhou, continuously innovating across the entire chain from basic formulas to clinical validation [2]. - The company is advancing multiple full-nutrition projects targeting specific diseases such as diabetes, tumors, and surgical trauma, with clinical value and product access efficiency leading the industry [2]. Group 3: Commercialization Strategy - Marsala has built a collaborative model of "in-hospital deep cultivation + out-of-hospital expansion," partnering with over 30 core hospitals nationwide to enhance nutritional services for patients [2]. - The company leverages its clinical resources to enter major retail channels like Bailian, Sam's Club, and Costco, promoting medical nutrition concepts to a broader consumer base [2]. Group 4: Investment and Future Outlook - The recent investment round led by Bailian Group and existing shareholders aims to empower Marsala's business growth through enhanced channel resources [3][4]. - Marsala's founder expressed confidence in the company's ability to innovate and expand its product offerings, contributing to the health of the Chinese population and supporting the Healthy China strategy [3][4].

低升糖食品和医学营养减重食品已进入知名大型商超。 本文为IPO早知道原创 作者｜C叔 微信公众号｜ipozaozhidao 据IPO早知道消息，近日，玛士撒拉（上海）生物科技有限公司（下称"玛士撒拉"）宣布完成近2亿 元B轮融资，由中金资本旗下基金、弘盛资本、弘晖基金联合领投，蜂巧资本、峰瑞资本跟投，凯乘 资本担任独家财务顾问。本轮融资将主要用于加速一系列医学营养品的开发，进一步扩大公司在特殊 医学营养、控能、DGI控糖三大业务板块的规模与领先优势。 玛士撒拉认为，中国的医学营养产业具备以下三个显著特征：1）市场需求庞大且尚未得到有效满 足。据统计，我国现存高血压患者2.45亿人、糖尿病患者1.3亿人、高脂血症患者2亿人，2024年度 实施手术总量达5280万例次，新增肿瘤患者近500万人。上述慢病人群及术后、肿瘤患者亟需专业 的医学营养产品及服务进行健康干预，但现有供给体系存在明显的缺口。尽管已获批的特医食品注册 证书超过200张，但产品同质化问题突出，其中肿瘤特定疾病全营养产品仅获批1项，难以满足患者 的实际临床需求。 2）产业良性发展亟需政策体系持续完善。鉴于医学营养直接关乎患者生命健康，行业对监管标准 ...